Maureen G. Conlan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Maureen G. Conlan has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Jeffrey McCullough
From the Mayo Clinic, Rochester, Minnesota; the University of Minnesota, Minneapolis, Minnesota; Brigham and Women's Hospital, Boston, Massachusetts; the American Red Cross Blood Services, Farmington, Connecticut; the DeGowin Blood Center, University of Iowa, Iowa City, Iowa; Cerus Corp., Concord, California; and Transfusion Therapies, Baxter Healthcare Corp., Round Lake, Illinois
4 shared publicationsLaurence Corash
Cerus Corporation Concord, California University of California School of Medicine San Francisco, California
4 shared publicationsEdward Snyder
From the American Red Cross Blood Services, Penn‐Jersey Region, Philadelphia, Pennsylvania; the Yale University School of Medicine, New Haven, Connecticut; the American Red Cross Blood Services, Farmington, Connecticut; the Puget Sound Blood Center and the University of Washington School of Medicine, Seattle, Washington; the DeGowin Blood Center, University of Iowa, Iowa City, Iowa; the University of Minnesota, Minneapolis, Minnesota; and Cerus Corp., Concord, California
3 shared publicationsJin‐Sying Lin
From the Copenhagen University Hospital, Copenhagen, Denmark; the Cerus Corporation, Concord, California; and Baxter R&D Europe, Nivelles, Belgium
3 shared publicationsRonald G. Strauss
From the Mayo Clinic, Rochester, Minnesota; the University of Minnesota, Minneapolis, Minnesota; Brigham and Women's Hospital, Boston, Massachusetts; the American Red Cross Blood Services, Farmington, Connecticut; the DeGowin Blood Center, University of Iowa, Iowa City, Iowa; Cerus Corp., Concord, California; and Transfusion Therapies, Baxter Healthcare Corp., Round Lake, Illinois
3 shared publicationsKathryn Davis
University of Washington Seattle, Washington
2 shared publications
Latest Publications
- 1 December 2006
- Published by Wiley in Transfusion
- Vol. 46 (12) , 2211-2212
The above letter was sent to Slichter et al.; Drs Slichter and colleagues offered the following reply
- 1 December 2006
- Published by Wiley in Transfusion
- Vol. 46 (12) , 2211-2212
The above letter was sent to Slichter et al.; Drs Slichter and colleagues offered the following reply
- 13 February 2006
- Published by Wiley in Transfusion
- Vol. 46 (4) , 562-571
Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial
BACKGROUND: A photochemical treatment (PCT) system has been developed to inactivate a broad spectrum of pathogens and white blood cells in platelet (PLT) products. The system comprises PLT additive solution (PAS III), amotosalen HCl, a compound adsorption device (CAD), a microprocessor‐controlled ultraviolet A light source, and a commercially assembled system of interconnected plastic containers.STUDY DESIGN AND METHODS: A clinical prototype of the PCT system was used in a large, randomized, controlled, double‐blind, Phase III clinical trial (SPRINT) that compared the efficacy and safety of PCT apheresis PLTs to untreated apheresis PLTs. The ability of multiple users was assessed in a blood center setting to perform the PCT and meet target process specifications.RESULTS: Each parameter was evaluated for 2237 to 2855 PCT PLT products. PCT requirements with respect to mean PLT dose, volume, and plasma content were met. Transfused PCT PLT products contained a mean of 3.6 × 1011 ± 0.7 × 1011 PLTs. The clinical process, which included trial‐specific samples, resulted in a mean PLT loss of 0.8 × 1011 ± 0.6 × 1011 PLTs per product. CAD treatment effectively reduced the amotosalen concentration from a mean of 31.9 ± 5.3 µmol per L after illumination to a mean of 0.41 ± 0.56 µmol per L after CAD. In general, there was little variation between sites for any parameter.CONCLUSIONS: The PCT process was successfully implemented by 12 blood centers in the United States to produce PCT PLTs used in a prospective, randomized trial where therapeutic efficacy of PCT PLTs was demonstrated. Process control was achieved under blood bank operating conditions.
- 13 February 2006
- Published by Wiley in Transfusion
- Vol. 46 (4) , 562-571
Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial
BACKGROUND: A photochemical treatment (PCT) system has been developed to inactivate a broad spectrum of pathogens and white blood cells in platelet (PLT) products. The system comprises PLT additive solution (PAS III), amotosalen HCl, a compound adsorption device (CAD), a microprocessor‐controlled ultraviolet A light source, and a commercially assembled system of interconnected plastic containers.STUDY DESIGN AND METHODS: A clinical prototype of the PCT system was used in a large, randomized, controlled, double‐blind, Phase III clinical trial (SPRINT) that compared the efficacy and safety of PCT apheresis PLTs to untreated apheresis PLTs. The ability of multiple users was assessed in a blood center setting to perform the PCT and meet target process specifications.RESULTS: Each parameter was evaluated for 2237 to 2855 PCT PLT products. PCT requirements with respect to mean PLT dose, volume, and plasma content were met. Transfused PCT PLT products contained a mean of 3.6 × 1011 ± 0.7 × 1011 PLTs. The clinical process, which included trial‐specific samples, resulted in a mean PLT loss of 0.8 × 1011 ± 0.6 × 1011 PLTs per product. CAD treatment effectively reduced the amotosalen concentration from a mean of 31.9 ± 5.3 µmol per L after illumination to a mean of 0.41 ± 0.56 µmol per L after CAD. In general, there was little variation between sites for any parameter.CONCLUSIONS: The PCT process was successfully implemented by 12 blood centers in the United States to produce PCT PLTs used in a prospective, randomized trial where therapeutic efficacy of PCT PLTs was demonstrated. Process control was achieved under blood bank operating conditions.
- 26 January 2006
- Published by Wiley in Transfusion
- Vol. 46 (3) , 424-433
Transfusion of 7‐day‐old amotosalen photochemically treated buffy‐coat platelets to patients with thrombocytopenia: a pilot study
Photochemical treatment (PCT) of platelets (PLTs) with amotosalen and ultraviolet A light to inactivate bacteria may facilitate extension of storage from 5 to 7 days. A randomized, double-blinded, crossover, noninferiority, single-site pilot study utilizing pooled buffy-coat PLTs was conducted. The primary endpoint was the 1-hour corrected count increment (CCI) after one transfusion each of 7-day-old PCT and reference (R) PLT components. Secondary endpoints included 1-hour count increment, time to next transfusion, hemostasis, transfusion reactions, and serious adverse events. Twenty patients with thrombocytopenia were randomly assigned: 9 to the PCT-R sequence and 11 to the R-PCT sequence. A significant treatment-by-period interaction was observed. Therefore, the first period only was also analyzed for the primary endpoint. Including both treatment periods, mean 1-hour CCI was 6587 +/- 4531 for PCT versus 8935 +/- 5478 for R-PLTs. For the first period only, mean 1-hour CCI was 8739 +/- 3785 for PCT versus 7433 +/- 5408 for R-PLTs. The upper bound of the one-sided 95 percent confidence interval of 2400 for the mean difference was higher than the specified noninferiority margin of 2200 for both analyses. Overall median time to next transfusion was 22 hours for PCT versus 27 hours for R-PLTs. Hemostasis was adequate and no transfusion reactions or serious adverse events were reported. Although this pilot study of a limited number of patients failed to show noninferiority within the specified noninferiority margin, 7-day-old PCT PLTs showed acceptable efficacy and safety for support of thrombocytopenia. The results, however, warrant evaluation in a larger trial of 7-day-old PCT PLTs.
- 26 January 2006
- Published by Wiley in Transfusion
- Vol. 46 (3) , 424-433
Transfusion of 7‐day‐old amotosalen photochemically treated buffy‐coat platelets to patients with thrombocytopenia: a pilot study
Photochemical treatment (PCT) of platelets (PLTs) with amotosalen and ultraviolet A light to inactivate bacteria may facilitate extension of storage from 5 to 7 days. A randomized, double-blinded, crossover, noninferiority, single-site pilot study utilizing pooled buffy-coat PLTs was conducted. The primary endpoint was the 1-hour corrected count increment (CCI) after one transfusion each of 7-day-old PCT and reference (R) PLT components. Secondary endpoints included 1-hour count increment, time to next transfusion, hemostasis, transfusion reactions, and serious adverse events. Twenty patients with thrombocytopenia were randomly assigned: 9 to the PCT-R sequence and 11 to the R-PCT sequence. A significant treatment-by-period interaction was observed. Therefore, the first period only was also analyzed for the primary endpoint. Including both treatment periods, mean 1-hour CCI was 6587 +/- 4531 for PCT versus 8935 +/- 5478 for R-PLTs. For the first period only, mean 1-hour CCI was 8739 +/- 3785 for PCT versus 7433 +/- 5408 for R-PLTs. The upper bound of the one-sided 95 percent confidence interval of 2400 for the mean difference was higher than the specified noninferiority margin of 2200 for both analyses. Overall median time to next transfusion was 22 hours for PCT versus 27 hours for R-PLTs. Hemostasis was adequate and no transfusion reactions or serious adverse events were reported. Although this pilot study of a limited number of patients failed to show noninferiority within the specified noninferiority margin, 7-day-old PCT PLTs showed acceptable efficacy and safety for support of thrombocytopenia. The results, however, warrant evaluation in a larger trial of 7-day-old PCT PLTs.
- 22 December 2005
- Published by Wiley in Transfusion
- Vol. 46 (1) , 24-33
Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light
The SPRINT trial examined efficacy and safety of photochemically treated (PCT) platelets (PLTs). PCT PLTs were equivalent to untreated (control) PLTs for prevention of bleeding. Transfused PLT dose and corrected count increments (CIs), however, were lower and transfusion intervals were shorter for PCT PLTs, resulting in more PCT than control transfusions. PLT dose was analyzed to determine the impact of the number of PLTs transfused on transfusion requirements. Transfusion response was compared for patients with all doses of >or=3.0 x 10(11) and the complementary subset of patients with any dose of fewer than 3.0 x 10(11). Analyses included comparison of bleeding, number of PLT and red blood cell (RBC) transfusions, transfusion intervals, and CIs between PCT and control groups within each PLT dose subset. Mean PLT dose per transfusion in the PCT group was lower than in the control group (3.7 x 10(11) vs. 4.0 x 10(11); p<0.001). More PCT patients received PLT doses of fewer than 3.0 x 10(11) (n=190) than control patients (n=118; p<0.01). Comparisons of patients receiving comparable PLT doses showed no significant differences between PCT and control groups for bleeding or number of PLT or RBC transfusions; however, transfusion intervals and CIs were significantly better for the control group. When patients were supported with comparable doses of PCT or conventional PLTs, the mean number of PLT transfusions was similar. Lower CIs and shorter transfusion intervals for PCT PLTs suggest that some PLT injury may occur during PCT. This injury does not result in a detectable increase in bleeding, however.
- 22 December 2005
- Published by Wiley in Transfusion
- Vol. 46 (1) , 24-33
Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light
The SPRINT trial examined efficacy and safety of photochemically treated (PCT) platelets (PLTs). PCT PLTs were equivalent to untreated (control) PLTs for prevention of bleeding. Transfused PLT dose and corrected count increments (CIs), however, were lower and transfusion intervals were shorter for PCT PLTs, resulting in more PCT than control transfusions. PLT dose was analyzed to determine the impact of the number of PLTs transfused on transfusion requirements. Transfusion response was compared for patients with all doses of >or=3.0 x 10(11) and the complementary subset of patients with any dose of fewer than 3.0 x 10(11). Analyses included comparison of bleeding, number of PLT and red blood cell (RBC) transfusions, transfusion intervals, and CIs between PCT and control groups within each PLT dose subset. Mean PLT dose per transfusion in the PCT group was lower than in the control group (3.7 x 10(11) vs. 4.0 x 10(11); p<0.001). More PCT patients received PLT doses of fewer than 3.0 x 10(11) (n=190) than control patients (n=118; p<0.01). Comparisons of patients receiving comparable PLT doses showed no significant differences between PCT and control groups for bleeding or number of PLT or RBC transfusions; however, transfusion intervals and CIs were significantly better for the control group. When patients were supported with comparable doses of PCT or conventional PLTs, the mean number of PLT transfusions was similar. Lower CIs and shorter transfusion intervals for PCT PLTs suggest that some PLT injury may occur during PCT. This injury does not result in a detectable increase in bleeding, however.
- 10 October 2005
- Published by Wiley in Transfusion
- Vol. 45 (12) , 1864-1875
Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial
BACKGROUND: A photochemical treatment (PCT) method utilizing a novel psoralen, amotosalen HCl, with ultraviolet A illumination has been developed to inactivate viruses, bacteria, protozoa, and white blood cells in platelet (PLT) concentrates. A randomized, controlled, double‐blind, Phase III trial (SPRINT) evaluated hemostatic efficacy and safety of PCT apheresis PLTs compared to untreated conventional (control) apheresis PLTs in 645 thrombocytopenic oncology patients requiring PLT transfusion support. Hemostatic equivalency was demonstrated. The proportion of patients with Grade 2 bleeding was not inferior for PCT PLTs.STUDY DESIGN AND METHODS: To further assess the safety of PCT PLTs, the adverse event (AE) profile of PCT PLTs transfused in the SPRINT trial is reported. Safety assessments included transfusion reactions, AEs, and deaths in patients treated with PCT or control PLTs in the SPRINT trial.RESULTS: A total of 4719 study PLT transfusions were given (2678 PCT and 2041 control). Transfusion reactions were significantly fewer following transfusion of PCT than control PLTs (3.0% vs. 4.1%; p = 0.02). Overall AEs (99.7% PCT vs. 98.2% control), Grade 3 or 4 AEs (79% PCT vs. 79% control), thrombotic AEs (3.8% PCT vs. 3.7% control), and deaths (3.5% PCT vs. 5.2% control) were comparable between treatment groups. Minor hemorrhagic AEs (petechiae [39% PCT vs. 29% control; p < 0.01] and fecal occult blood [33% PCT vs. 25% control; p = 0.03]) and skin rashes (56% PCT vs. 42% control; p < 0.001) were significantly more frequent in the PCT group.CONCLUSION: The overall safety profile of PCT PLTs was comparable to untreated PLTs.
- 10 October 2005
- Published by Wiley in Transfusion
- Vol. 45 (12) , 1864-1875
Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial
BACKGROUND: A photochemical treatment (PCT) method utilizing a novel psoralen, amotosalen HCl, with ultraviolet A illumination has been developed to inactivate viruses, bacteria, protozoa, and white blood cells in platelet (PLT) concentrates. A randomized, controlled, double‐blind, Phase III trial (SPRINT) evaluated hemostatic efficacy and safety of PCT apheresis PLTs compared to untreated conventional (control) apheresis PLTs in 645 thrombocytopenic oncology patients requiring PLT transfusion support. Hemostatic equivalency was demonstrated. The proportion of patients with Grade 2 bleeding was not inferior for PCT PLTs.STUDY DESIGN AND METHODS: To further assess the safety of PCT PLTs, the adverse event (AE) profile of PCT PLTs transfused in the SPRINT trial is reported. Safety assessments included transfusion reactions, AEs, and deaths in patients treated with PCT or control PLTs in the SPRINT trial.RESULTS: A total of 4719 study PLT transfusions were given (2678 PCT and 2041 control). Transfusion reactions were significantly fewer following transfusion of PCT than control PLTs (3.0% vs. 4.1%; p = 0.02). Overall AEs (99.7% PCT vs. 98.2% control), Grade 3 or 4 AEs (79% PCT vs. 79% control), thrombotic AEs (3.8% PCT vs. 3.7% control), and deaths (3.5% PCT vs. 5.2% control) were comparable between treatment groups. Minor hemorrhagic AEs (petechiae [39% PCT vs. 29% control; p < 0.01] and fecal occult blood [33% PCT vs. 25% control; p = 0.03]) and skin rashes (56% PCT vs. 42% control; p < 0.001) were significantly more frequent in the PCT group.CONCLUSION: The overall safety profile of PCT PLTs was comparable to untreated PLTs.
- 2 December 2004
- Published by Wiley in Transfusion
- Vol. 44 (12) , 1732-1740
Recovery and life span of 111indium‐radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S‐59) and ultraviolet A light
BACKGROUND: A photochemical treatment (PCT) method to inactivate pathogens in platelet concentrates has been developed. The system uses a psoralen, amotosalen HCl, coupled with ultraviolet A (UVA) illumination.STUDY DESIGN AND METHODS: Three sequential clinical trials evaluated viability of PCT platelets prepared with a prototype device. Posttransfusion recovery and lifespan of 111Indium‐labeled autologous 5 day‐old platelets in healthy subjects was assessed. In the first study, 23 subjects received transfusions of autologous PCT and/or control platelets. In a second study, 16 of these subjects received PCT platelets processed with a Compound Adsorption Device (CAD) (PCT‐CAD) to reduce patient exposure to residual amotosalen. In the third study, the effect of gamma‐irradiation on PCT platelets was studied. Data from control transfusions from Study A were used for paired comparisons in the latter 2 studies.RESULTS: Mean PCT‐CAD platelet recovery for the 16 subjects with paired data was 42.5 ± 8.7% versus 50.3 ± 7.7% for control platelets, mean difference of 7.8% (p < 0.01). Mean lifespan for PCT‐CAD platelets was 4.8 days (±1.3) versus 6.0 days (±1.2) for control platelets, mean difference of 1.3 days (p < 0.01). Platelet recovery and lifespan were similar to PCT‐CAD for PCT without CAD treatment and PCT‐CAD with gamma‐irradiation.CONCLUSION: Viability of 5 day‐old PCT platelets was less than for control platelets. However, both were within ranges reported for 5 day‐old platelets.
- 2 December 2004
- Published by Wiley in Transfusion
- Vol. 44 (12) , 1732-1740
Recovery and life span of 111indium‐radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S‐59) and ultraviolet A light
BACKGROUND: A photochemical treatment (PCT) method to inactivate pathogens in platelet concentrates has been developed. The system uses a psoralen, amotosalen HCl, coupled with ultraviolet A (UVA) illumination.STUDY DESIGN AND METHODS: Three sequential clinical trials evaluated viability of PCT platelets prepared with a prototype device. Posttransfusion recovery and lifespan of 111Indium‐labeled autologous 5 day‐old platelets in healthy subjects was assessed. In the first study, 23 subjects received transfusions of autologous PCT and/or control platelets. In a second study, 16 of these subjects received PCT platelets processed with a Compound Adsorption Device (CAD) (PCT‐CAD) to reduce patient exposure to residual amotosalen. In the third study, the effect of gamma‐irradiation on PCT platelets was studied. Data from control transfusions from Study A were used for paired comparisons in the latter 2 studies.RESULTS: Mean PCT‐CAD platelet recovery for the 16 subjects with paired data was 42.5 ± 8.7% versus 50.3 ± 7.7% for control platelets, mean difference of 7.8% (p < 0.01). Mean lifespan for PCT‐CAD platelets was 4.8 days (±1.3) versus 6.0 days (±1.2) for control platelets, mean difference of 1.3 days (p < 0.01). Platelet recovery and lifespan were similar to PCT‐CAD for PCT without CAD treatment and PCT‐CAD with gamma‐irradiation.CONCLUSION: Viability of 5 day‐old PCT platelets was less than for control platelets. However, both were within ranges reported for 5 day‐old platelets.
- 1 September 2002
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 96 (Sup 2) , A189
Platelets Treated with the INTERCEPT System for Pathogen Inactivation Provide Hemostasis in Severely Thrombocytopenic Patients
- 1 September 2002
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 96 (Sup 2) , A189
Platelets Treated with the INTERCEPT System for Pathogen Inactivation Provide Hemostasis in Severely Thrombocytopenic Patients